AAPL326.57+11.23 (+3.56%) ▲|ABBV255.00+4.09 (+1.63%) ▲|ABT103.36-1.87 (-1.78%) ▼|ACN177.91+2.11 (+1.20%) ▲|ADBE248.83-6.03 (-2.37%) ▼|AMAT454.01-14.84 (-3.17%) ▼|AMD503.60-17.50 (-3.36%) ▼|AMGN382.47-8.80 (-2.25%) ▼|AMT172.98-2.45 (-1.40%) ▼|AMZN251.89-0.51 (-0.20%) ▼|AVGO360.83-3.55 (-0.97%) ▼|AXP320.71-1.09 (-0.34%) ▼|BA204.80-1.62 (-0.78%) ▼|BAC62.56-0.11 (-0.18%) ▼|BKNG174.33+0.90 (+0.52%) ▲|BLK1,062.40-9.63 (-0.90%) ▼|BMY63.75-0.66 (-1.02%) ▼|BNY162.59+0.08 (+0.05%) ▲|BRK-B507.00+0.28 (+0.06%) ▲|C138.50+0.70 (+0.51%) ▲|CAT805.00-10.56 (-1.29%) ▼|CL87.90-0.13 (-0.15%) ▼|CMCSA25.17+0.58 (+2.36%) ▲|COF207.11-3.75 (-1.78%) ▼|COP137.04+0.51 (+0.37%) ▲|COST902.38-0.22 (-0.02%) ▼|CRM243.00-1.16 (-0.48%) ▼|CSCO107.44-1.99 (-1.82%) ▼|CVS95.29-0.09 (-0.09%) ▼|CVX212.76-1.05 (-0.49%) ▼|DE677.94+0.73 (+0.11%) ▲|DHR200.53-4.32 (-2.11%) ▼|DIS105.82+1.64 (+1.57%) ▲|DUK119.37-1.06 (-0.88%) ▼|EMR148.37-1.97 (-1.31%) ▼|FDX311.80+2.61 (+0.84%) ▲|GD354.25+1.58 (+0.45%) ▲|GE324.15-1.27 (-0.39%) ▼|GEV923.91-27.13 (-2.85%) ▼|GILD144.81-0.84 (-0.58%) ▼|GM86.12+2.36 (+2.82%) ▲|GOOG330.39+2.01 (+0.61%) ▲|GOOGL332.60+1.95 (+0.59%) ▲|GS1,019.77-9.01 (-0.88%) ▼|HD305.69-4.76 (-1.53%) ▼|HON202.18-2.75 (-1.34%) ▼|IBM234.02-5.92 (-2.47%) ▼|INTC100.32-5.92 (-5.57%) ▼|INTU312.77-1.17 (-0.37%) ▼|ISRG360.46+7.22 (+2.04%) ▲|JNJ266.35-0.73 (-0.27%) ▼|JPM353.56-1.15 (-0.32%) ▼|KO87.83+0.28 (+0.32%) ▲|LIN461.62-5.03 (-1.08%) ▼|LLY1,123.00-1.21 (-0.11%) ▼|LMT530.12+5.66 (+1.08%) ▲|LOW196.59-2.01 (-1.01%) ▼|LRCX298.01-17.83 (-5.65%) ▼|MA565.37-2.13 (-0.38%) ▼|MCD253.05-0.43 (-0.17%) ▼|MDLZ62.47+0.05 (+0.08%) ▲|MDT91.62-0.27 (-0.29%) ▼|META644.38-9.31 (-1.42%) ▼|MMM162.86-1.54 (-0.94%) ▼|MO68.79+0.90 (+1.33%) ▲|MRK144.71-2.82 (-1.91%) ▼|MS212.66-2.69 (-1.25%) ▼|MSFT492.44+0.79 (+0.16%) ▲|MU977.41-50.36 (-4.90%) ▼|NEE82.44-0.21 (-0.25%) ▼|NFLX76.01-0.02 (-0.03%) ▼|NKE36.62-0.73 (-1.95%) ▼|NOW131.17+0.06 (+0.05%) ▲|NVDA218.36-5.31 (-2.37%) ▼|ORCL152.94-8.69 (-5.38%) ▼|PEP136.65-0.04 (-0.03%) ▼|PFE27.65-0.13 (-0.47%) ▼|PG142.97+0.33 (+0.23%) ▲|PLTR165.86-3.67 (-2.16%) ▼|PM189.77+4.06 (+2.19%) ▲|QCOM176.88+0.48 (+0.27%) ▲|RTX198.12+0.57 (+0.29%) ▲|SBUX99.22-0.82 (-0.82%) ▼|SCHW107.33+0.79 (+0.74%) ▲|SO87.75-0.59 (-0.67%) ▼|SPG204.67+0.14 (+0.07%) ▲|T25.55+0.40 (+1.59%) ▲|TMO603.18-2.51 (-0.41%) ▼|TMUS177.16-0.18 (-0.10%) ▼|TSLA363.56-4.25 (-1.16%) ▼|TXN258.82-2.77 (-1.06%) ▼|UBER72.56+1.48 (+2.08%) ▲|UNH388.28-4.78 (-1.22%) ▼|UNP285.78+1.04 (+0.37%) ▲|UPS99.97+0.75 (+0.76%) ▲|USB62.41+0.30 (+0.48%) ▲|V367.21-0.18 (-0.05%) ▼|VZ49.97+0.23 (+0.46%) ▲|WFC89.45-0.22 (-0.25%) ▼|WMT105.73-0.10 (-0.09%) ▼|XOM165.23+1.00 (+0.61%) ▲|AAPL326.57+11.23 (+3.56%) ▲|ABBV255.00+4.09 (+1.63%) ▲|ABT103.36-1.87 (-1.78%) ▼|ACN177.91+2.11 (+1.20%) ▲|ADBE248.83-6.03 (-2.37%) ▼|AMAT454.01-14.84 (-3.17%) ▼|AMD503.60-17.50 (-3.36%) ▼|AMGN382.47-8.80 (-2.25%) ▼|AMT172.98-2.45 (-1.40%) ▼|AMZN251.89-0.51 (-0.20%) ▼|AVGO360.83-3.55 (-0.97%) ▼|AXP320.71-1.09 (-0.34%) ▼|BA204.80-1.62 (-0.78%) ▼|BAC62.56-0.11 (-0.18%) ▼|BKNG174.33+0.90 (+0.52%) ▲|BLK1,062.40-9.63 (-0.90%) ▼|BMY63.75-0.66 (-1.02%) ▼|BNY162.59+0.08 (+0.05%) ▲|BRK-B507.00+0.28 (+0.06%) ▲|C138.50+0.70 (+0.51%) ▲|CAT805.00-10.56 (-1.29%) ▼|CL87.90-0.13 (-0.15%) ▼|CMCSA25.17+0.58 (+2.36%) ▲|COF207.11-3.75 (-1.78%) ▼|COP137.04+0.51 (+0.37%) ▲|COST902.38-0.22 (-0.02%) ▼|CRM243.00-1.16 (-0.48%) ▼|CSCO107.44-1.99 (-1.82%) ▼|CVS95.29-0.09 (-0.09%) ▼|CVX212.76-1.05 (-0.49%) ▼|DE677.94+0.73 (+0.11%) ▲|DHR200.53-4.32 (-2.11%) ▼|DIS105.82+1.64 (+1.57%) ▲|DUK119.37-1.06 (-0.88%) ▼|EMR148.37-1.97 (-1.31%) ▼|FDX311.80+2.61 (+0.84%) ▲|GD354.25+1.58 (+0.45%) ▲|GE324.15-1.27 (-0.39%) ▼|GEV923.91-27.13 (-2.85%) ▼|GILD144.81-0.84 (-0.58%) ▼|GM86.12+2.36 (+2.82%) ▲|GOOG330.39+2.01 (+0.61%) ▲|GOOGL332.60+1.95 (+0.59%) ▲|GS1,019.77-9.01 (-0.88%) ▼|HD305.69-4.76 (-1.53%) ▼|HON202.18-2.75 (-1.34%) ▼|IBM234.02-5.92 (-2.47%) ▼|INTC100.32-5.92 (-5.57%) ▼|INTU312.77-1.17 (-0.37%) ▼|ISRG360.46+7.22 (+2.04%) ▲|JNJ266.35-0.73 (-0.27%) ▼|JPM353.56-1.15 (-0.32%) ▼|KO87.83+0.28 (+0.32%) ▲|LIN461.62-5.03 (-1.08%) ▼|LLY1,123.00-1.21 (-0.11%) ▼|LMT530.12+5.66 (+1.08%) ▲|LOW196.59-2.01 (-1.01%) ▼|LRCX298.01-17.83 (-5.65%) ▼|MA565.37-2.13 (-0.38%) ▼|MCD253.05-0.43 (-0.17%) ▼|MDLZ62.47+0.05 (+0.08%) ▲|MDT91.62-0.27 (-0.29%) ▼|META644.38-9.31 (-1.42%) ▼|MMM162.86-1.54 (-0.94%) ▼|MO68.79+0.90 (+1.33%) ▲|MRK144.71-2.82 (-1.91%) ▼|MS212.66-2.69 (-1.25%) ▼|MSFT492.44+0.79 (+0.16%) ▲|MU977.41-50.36 (-4.90%) ▼|NEE82.44-0.21 (-0.25%) ▼|NFLX76.01-0.02 (-0.03%) ▼|NKE36.62-0.73 (-1.95%) ▼|NOW131.17+0.06 (+0.05%) ▲|NVDA218.36-5.31 (-2.37%) ▼|ORCL152.94-8.69 (-5.38%) ▼|PEP136.65-0.04 (-0.03%) ▼|PFE27.65-0.13 (-0.47%) ▼|PG142.97+0.33 (+0.23%) ▲|PLTR165.86-3.67 (-2.16%) ▼|PM189.77+4.06 (+2.19%) ▲|QCOM176.88+0.48 (+0.27%) ▲|RTX198.12+0.57 (+0.29%) ▲|SBUX99.22-0.82 (-0.82%) ▼|SCHW107.33+0.79 (+0.74%) ▲|SO87.75-0.59 (-0.67%) ▼|SPG204.67+0.14 (+0.07%) ▲|T25.55+0.40 (+1.59%) ▲|TMO603.18-2.51 (-0.41%) ▼|TMUS177.16-0.18 (-0.10%) ▼|TSLA363.56-4.25 (-1.16%) ▼|TXN258.82-2.77 (-1.06%) ▼|UBER72.56+1.48 (+2.08%) ▲|UNH388.28-4.78 (-1.22%) ▼|UNP285.78+1.04 (+0.37%) ▲|UPS99.97+0.75 (+0.76%) ▲|USB62.41+0.30 (+0.48%) ▲|V367.21-0.18 (-0.05%) ▼|VZ49.97+0.23 (+0.46%) ▲|WFC89.45-0.22 (-0.25%) ▼|WMT105.73-0.10 (-0.09%) ▼|XOM165.23+1.00 (+0.61%) ▲|
22.6 C
New York
Friday, September 11, 2026

Tag: 6

JEF INVESTIGATION: Robbins Geller Rudman & Dowd LLP Launches Investigation into Jefferies Financial Group, Inc. and Encourages Investors and Potential Witnesses to Contact Law...

We are investigating whether Jefferies Financial Group Inc. & certain of its top executives made materially false &/or misleading statements to investors.

ELWT Investor News: If You Have Suffered Losses in Elauwit Connection, Inc. (NASDAQ: ELWT), You Are Encouraged to Contact The Rosen Law Firm About...

NEW YORK, June 05, 2026 (GLOBE NEWSWIRE) --

Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Elauwit Connection, Inc. (NASDAQ: ELWT) resulting from allegations that Elauwit may have issued materially misleading business information to the investing public.

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

$8.5 million upfront with up to approximately $15.2 million of potential additional gross proceeds upon the exercise in full of warrants

DentaQuest Data Breach: Edelson Lechtzin LLP Launches Investigation Into Exposure of Personal Information

Edelson Lechtzin LLP is investigating data privacy claims arising from the DentaQuest data breach.

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with...

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and AID Use

Ambrosia Biosciences Announces Preclinical Data Supporting Differentiated Profile of AMB-702, its Novel Small Molecule GLP-1 Receptor Agonist Development Candidate

AMB-702 demonstrates superior target coverage and efficacy in lean non-human primates The dataset was shared as part of a poster presentation at the American Diabetes...

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing...

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes 
• Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients treated with icovamenib, with no evidence of immune activation, and inflammatory markers stable or reduced
• Additionally, the Company expanded its Phase I BMF-650 study to evaluate a rapid one-step titration and enhanced weight loss potential with its oral GLP-1 receptor agonist

Machine Learning Model Accurately Predicts Long-Term Risk of Type 2 Diabetes

Study of Over Three Million Patients for Risk of Type 2 Diabetes Demonstrates Potential for More Advanced Approach to Early IdentificationNEW ORLEANS, June 5,...

Novo Nordisk’s investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes–presented at ADA 2026

A phase 2 study of investigational once-weekly subcutaneous zenagamtide showed statistically significant reductions in blood sugar in adults with type 2 diabetes compared to...

HELE Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Helen of Troy Limited. Class Action Lawsuit

Robbins LLP is Investigating Allegations that Helen of Troy Limited (HELE) Misled Investors Regarding the Ability of Project Pegasus to Improve Efficiency

First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control

Phase 2 Study Results Highlight Use of Once-Daily Injection for Weight Loss and Reduction in Insulin UseNEW ORLEANS, June 5, 2026 /PRNewswire/ -- A...

Guild Wars 3, Modern Evolution of the MMORPG, Announced at Summer Game Fest for PC and PlayStation 5

The First Time a Game in the Legendary Franchise Comes to ConsolesBELLEVUE, Wash., June 6, 2026 /PRNewswire/ -- Critically-acclaimed game development studio ArenaNet® tonight...

Orca Energy Group Inc. Announces Completion of Q1 2026 Interim Filings

TORTOLA, British Virgin Islands, June 05, 2026 (GLOBE NEWSWIRE) -- Orca Energy Group Inc. (“Orca” or the “Company” and includes its subsidiaries and affiliates) (TSX-V: ORC.A, ORC.B) today announces that it has filed its condensed consolidated interim (unaudited) financial statements and management’s discussion and analysis for the three month period ended March 31, 2026 (“Q1 2026”) with the Canadian securities regulatory authorities. All amounts are in United States dollars (“$”) unless otherwise stated.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTags6